Kara‐Louise Royle

A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study

Gordon Cook, Kara‐Louise Royle, Charlotte Pawlyn et al. · The Lancet Haematology · 2019 · 103 citations · Full text

Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial

Janet E. Brown, Kara‐Louise Royle, Walter M. Gregory et al. · The Lancet Oncology · 2023 · 76 citations · Full text

<i>F</i> railty-adjusted therapy <i>i</i> n <i>T</i> ransplant <i>N</i> on- <i>E</i> ligible patient <i>s</i> with newly diagno <i>s</i> ed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial

Amy Beth Coulson, Kara‐Louise Royle, Charlotte Pawlyn et al. · BMJ Open · 2022 · 33 citations · Full text

Prognosis research ideally should measure time-varying predictors at their intended moment of use

Rebecca Whittle, Kara‐Louise Royle, Kelvin P. Jordan et al. · Diagnostic and Prognostic Research · 2017 · 28 citations · Full text

Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma <scp>IX</scp> randomised study

Kara‐Louise Royle, Walter M. Gregory, David A. Cairns et al. · British Journal of Haematology · 2018 · 24 citations · Full text